CORONA Remedies declares ₹10 dividend for FY26
CORONA Remedies has recommended a final dividend of ₹10 per equity share for FY26, subject to AGM approval, with a record date of June 19, 2026. The company detailed TDS regulations under the Income Tax Act, 2025, specifying rates for residents and non-residents. Shareholders must submit necessary documents like Form 121 and Tax Residency Certificates by June 19, 2026, to avail of beneficial tax rates.
*this image is generated using AI for illustrative purposes only.
CORONA Remedies has announced a final dividend of ₹10 per equity share for the financial year 2025-26. The Board of Directors recommended the dividend at a meeting held on May 11, 2026. This payout is subject to approval by shareholders at the ensuing 22nd Annual General Meeting.
The dividend will be paid to shareholders whose names appear in the Register of Members or Register of Beneficial Owners as on Friday, June 19, 2026. The company stated that bank particulars registered with Depository Participants would be used for the payment. Shareholders have been requested to update their address, bank mandate, PAN, and KYC details with their Depository Participants before the record date to ensure timely credit.
Tax Deduction at Source
The company informed shareholders that it is required to withhold tax on dividends in accordance with the Income Tax Act, 2025. The applicable tax rate varies based on the residential status of the shareholder and the documents submitted. Shareholders must update or verify their PAN, address, email, and residential status with their Depository Participants. The company will rely on details available with the Registrar to Issue and Share Transfer Agent, Bigshare Services Private Limited.
TDS Rates for Resident Shareholders
The communication outlined specific Tax Deducted at Source (TDS) rates for different categories of resident shareholders. The table below details the applicable rates and conditions.
| Category | TDS Rate | Conditions |
|---|---|---|
| Dividend ≤ ₹10,000 | Nil | Aggregate dividend does not exceed ₹10,000 or Form 121 is furnished. |
| Dividend > ₹10,000 | 10% | Shareholder has valid PAN and does not furnish Form 121. |
| Invalid PAN | 20% | Shareholder does not have PAN or invalid PAN. |
TDS Rates for Non-Resident Shareholders
For non-resident shareholders, tax will be deducted at 20% plus applicable surcharge and cess, or the tax treaty rate, whichever is beneficial. Specific documents, such as a Tax Residency Certificate and digital Form 41, are mandatory to avail of the beneficial treaty rate. Sovereign Wealth funds and Pension funds notified by the Central Government are eligible for a NIL TDS rate upon submission of necessary declarations.
Shareholders are required to submit relevant documents, including Form 121 and self-declarations, to the company's Registrar via email at tds@bigshareonline.com on or before June 19, 2026. Any communication received after this date will not be considered for tax rate determination.
Historical Stock Returns for Corona Remedies
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.99% | -4.28% | +4.30% | +18.27% | +18.27% | +18.27% |
How does CORONA Remedies' ₹10 per share dividend compare to its historical payout trend, and does it signal sustained profitability growth for FY2026-27?
Could the introduction of the Income Tax Act, 2025's revised TDS framework significantly impact retail shareholder participation in dividend-paying stocks going forward?
What are the potential implications for CORONA Remedies' stock price and investor sentiment following shareholder approval at the 22nd AGM?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
